Discounted Cash Flow (DCF) Analysis Levered
Cassava Sciences, Inc. (SAVA)
$19.1854
+1.65 (+9.38%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 19.1,854 |
|---|---|
| Beta | -0.086 |
| Diluted Shares Outstanding | 40.20 |
| Cost of Debt | |
| Tax Rate | 4.95 |
| After-tax Cost of Debt | -2,580.72% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 4.334 |
| Total Debt | 0.14 |
| Total Equity | 771.29 |
| Total Capital | 771.43 |
| Debt Weighting | 0.02 |
| Equity Weighting | 99.98 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 3.87 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -200.88 |
| Equity Value | - |
| Shares Outstanding | 40.20 |
| Equity Value Per Share | - |